These findings are timely as the inclusion of CHEK2 on standard cancer predisposition gene panel tests means that many clinical genetics services are already using data related to CHEK2 pathogenic variants to advise women and their families about breast cancer risk management. The gene discussed is CHEK2; the disease is breast cancer.